OXILAN-350
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXILAN-350 is an injectable diagnostic or contrast agent developed by Guerbet, approved in 1995. The specific mechanism of action and therapeutic indications are not publicly detailed in available data. The product is administered via injection and represents a mature pharmaceutical asset.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on defending market share rather than expansion, suggesting stable but resource-constrained roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OXILAN-350 currently shows zero linked job openings, reflecting its mature, stable status with limited growth trajectory. Career opportunities on this product are likely restricted to maintaining existing market position and managing the transition to post-LOE generic competition.
Brand ManagerField Sales Representative
Worked on OXILAN-350 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.